ArticlePLoS neglected tropical diseases2017
Improving our forecasts for trachoma elimination: What else do we need to know?
Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Dynamics of trachoma infection in West Africa revealed by a hidden state model.PLoS computational biology · 2026Article
- Modeling the "F" in "SAFE": The dynamic game of facial cleanliness in trachoma prevention.PloS one · 2023Article
- Predicting future community-level ocular Chlamydia trachomatis infection prevalence using serological, clinical, molecular, and geospatial data.PLoS neglected tropical diseases · 2022Article
- Modelling trachoma post-2020: opportunities for mitigating the impact of COVID-19 and accelerating progress towards elimination.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Article
- Utilizing Organoid and Air-Liquid Interface Models as a Screening Method in the Development of New Host Defense Peptides.Frontiers in cellular and infection microbiology · 2020Review
- Optimising sampling regimes and data collection to inform surveillance for trachoma control.PLoS neglected tropical diseases · 2018Article
- Models of Trachoma Transmission and Their Policy Implications: From Control to Elimination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Review
- Probabilistic forecasts of trachoma transmission at the district level: A statistical model comparison.Epidemics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) has targeted trachoma for elimination as a public health concern by 2020. Mathematical modelling is used for a range of infectious diseases to assess the impact of different intervention strategies on the prevalence of infection or disease. Here we evaluate the performance of four different mechanistic mathematical models that could all realistically represent trachoma transmission. We fit the four different mechanistic models of trachoma transmission to cross-sectional age-specific Polymerase Chain Reaction (PCR) and Trachomatous inflammation, follicular (TF) prevalence data. We estimate 4 or 3 parameters within each model, including the duration of an individual's infection and disease episode using Markov Chain Monte Carlo. We assess the performance of each models fit to the data by calculating the deviance information criterion. We then model the implementation of different interventions for each model structure to assess the feasibility of elimination of trachoma with different model structures. A model structure which allowed some re-infection in the disease state (Model 2) was statistically the most well performing model. All models struggled to fit to the very high prevalence of active disease in the youngest age group. Our simulations suggested that for Model 3, with annual antibiotic treatment and transmission reduction, the chance of reducing active disease prevalence to < 5% within 5 years was very low, while Model 2 and 4 could ensure that active disease prevalence was reduced within 5 years. Model 2 here fitted to the data best of the models evaluated. The appropriate level of susceptibility to re-infection was, however, challenging to identify given the amount and kind of data available. We demonstrate that the model structure assumed can lead to different end points following the implementation of the same interventions. Our findings are likely to extend beyond trachoma and should be considered when modelling other neglected tropical diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.